Cover Image
市場調查報告書

頭頸部腫瘤:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析

Head and neck cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365175
出版日期 內容資訊 英文 208 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
頭頸部腫瘤:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析 Head and neck cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年06月01日 內容資訊: 英文 208 Pages
簡介

本報告提供頭頸部腫瘤治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:頭頸部腫瘤

  • 摘要整理
  • 市場概要·趨勢
  • 市場定義·手法
  • Durvalumab
  • Erbitux (cetuximab)
  • Gilotrif (afatinib)
  • Javlor (vinflunine ditartrate)
  • Keytruda (pembrolizumab)
  • Multikine
  • Opdivo (nivolumab)
  • Reolysin
  • TS-1 (gimeracil/oteracil potassium/tegafur)
  • 1次調查手法

治療:頭頸部腫瘤

  • 摘要整理
  • 1次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢:I期·II期
  • 處方趨勢:III期
  • 處方趨勢:IV期

流行病學:頭頸部腫瘤

  • 摘要整理
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點

上市藥:頭頸部腫瘤

  • 摘要整理
  • 產品概要
  • 產品簡介: Erbitux

開發平台:頭頸部腫瘤

  • 摘要整理
  • 臨床實驗平台概要
  • 最近中止開發的藥
  • 比較治療
  • 產品簡介 (後期) :Gilotrif
  • 產品簡介 (後期) :Javlor
  • 產品簡介 (後期) :Keytruda
  • 產品簡介 (後期) :Multikine
  • 產品簡介 (後期) :Opdivo
  • 產品簡介 (後期) :Reolysin
  • 產品簡介 (後期) :durvalumab

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC12793

Revenues from new brands will offset the biosimilar and generic erosion of Erbitux and TS-1, enabling the net growth of the head and neck cancer market.

This report addresses the following questions:

  • Which pipeline therapies will have the largest impact on the head and neck cancer market?
  • Which pipeline therapies will be positioned in the platinum-resistant recurrent and/or metastatic treatment settings?
  • How will the current standard of care Erbitux fare following the launch of pipeline therapies and biosimilar cetuximab?
  • Which treatment settings are PD-1/PD-L1inhibitors Keytruda, Opdivo, and durvalumab being developed for and how are they expected to perform?
  • When will generic and biosimilar therapies enter the market and what impact will they have on overall market revenues?

TABLE OF CONTENTS

FORECAST: HEAD AND NECK CANCER

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Durvalumab
  • 5. Erbitux (cetuximab)
  • 6. Gilotrif (afatinib)
  • 7. Javlor (vinflunine ditartrate)
  • 8. Keytruda (pembrolizumab)
  • 9. Multikine
  • 10. Opdivo (nivolumab)
  • 11. Reolysin
  • 12. TS-1 (gimeracil/oteracil potassium/tegafur)
  • 13. Primary Research Methodology

TREATMENT: HEAD AND NECK CANCER

  • 14. Executive Summary
  • 15. Primary Research Methodology
  • 16. Disease Definition and Diagnosis
  • 17. Patient Segmentation
  • 18. Country Treatment Trees
  • 19. Current Treatment Options
  • 20. Prescribing Trends: Stage I and Stage II
  • 21. Prescribing Trends: Stage III
  • 22. Prescribing Trends: Stage IV

EPIDEMIOLOGY: HEAD AND NECK CANCER

  • 23. Executive Summary
  • 24. Sources and Methodology
  • 25. Forecast
  • 26. Epidemiologist Insight
  • 27. Strengths and Limitations

MARKETED DRUGS: HEAD AND NECK CANCER

  • 28. Executive Summary
  • 29. Product Overview
  • 30. Product profile: Erbitux

PIPELINE: HEAD AND NECK CANCER

  • 31. Executive Summary
  • 32. Clinical Pipeline Overview
  • 33. Recently Discontinued Drugs
  • 34. Comparator Therapy
  • 35. Product profile (late stage): Gilotrif
  • 36. Product profile (late stage): Javlor
  • 37. Product profile (late stage): Keytruda
  • 38. Product profile (late stage): Multikine
  • 39. Product profile (late stage): Opdivo
  • 40. Product profile (late stage): Reolysin
  • 41. Product profile (late stage): durvalumab
Back to Top